{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:21:24Z","timestamp":1794000084315,"version":"4.8.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00223-021-00838-z","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T19:02:57Z","timestamp":1616785377000},"page":"528-538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The Role of Bone Biopsy in the Management of CKD-MBD"],"prefix":"10.1007","volume":"108","author":[{"name":"the European Renal Osteodystrophy (EUROD), an initiative of the CKD-MBD working group of the ERA-EDTA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1323-5293","authenticated-orcid":false,"given":"Ana Carina","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8582-8258","authenticated-orcid":false,"given":"Martine","family":"Cohen-Solal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1463-6571","authenticated-orcid":false,"given":"Patrick C.","family":"D\u2019Haese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3300-6033","authenticated-orcid":false,"given":"An\u00edbal","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"838_CR1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Drueke T, Cunningham J et al (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69:1945\u20131953","journal-title":"Kidney Int"},{"key":"838_CR2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S2213-8587(14)70059-2","volume":"2","author":"MG Vervloet","year":"2014","unstructured":"Vervloet MG, Massy ZA, Brandenburg VM et al (2014) Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. Lancet Diabetes Endocrinol 2:427\u2013436","journal-title":"Lancet Diabetes Endocrinol"},{"key":"838_CR3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler M, Block GA, Evenepoel P et al (2017) Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what\u2019s changed and why it matters. Kidney Int 92:26\u201336","journal-title":"Kidney Int"},{"key":"838_CR4","first-page":"S1","volume":"113","author":"Kidney Disease: Improving Global Outcomes CKDMBDWG","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes CKDMBDWG (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113:S1-130","journal-title":"Kidney Int Suppl"},{"key":"838_CR5","first-page":"1608","volume":"32","author":"P Evenepoel","year":"2017","unstructured":"Evenepoel P, D\u2019Haese P, Bacchetta J et al (2017) Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative-a position paper. Nephrol Dial Transplant 32:1608\u20131613","journal-title":"Nephrol Dial Transplant"},{"key":"838_CR6","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.fertnstert.2019.10.005","volume":"112","author":"D Nandiraju","year":"2019","unstructured":"Nandiraju D, Ahmed I (2019) Human skeletal physiology and factors affecting its modeling and remodeling. Fertil Steril 112:775\u2013781","journal-title":"Fertil Steril"},{"key":"838_CR7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/nep.12570","volume":"21","author":"C Carvalho","year":"2016","unstructured":"Carvalho C, Magalhaes J, Pereira L, Simoes-Silva L, Castro-Ferreira I, Frazao JM (2016) Evolution of bone disease after kidney transplantation: a prospective histomorphometric analysis of trabecular and cortical bone. Nephrology 21:55\u201361","journal-title":"Nephrology"},{"key":"838_CR8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.bone.2017.01.023","volume":"100","author":"KA Hruska","year":"2017","unstructured":"Hruska KA, Sugatani T, Agapova O, Fang Y (2017) The chronic kidney disease: mineral bone disorder (CKD-MBD): advances in pathophysiology. Bone 100:80\u201386","journal-title":"Bone"},{"key":"838_CR9","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40620-017-0404-z","volume":"30","author":"J Bover","year":"2017","unstructured":"Bover J, Bailone L, Lopez-Baez V et al (2017) Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. J Nephrol 30:677\u2013687","journal-title":"J Nephrol"},{"key":"838_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"Kidney Disease: Improving Global Outcomes CKDMBDUWG","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes CKDMBDUWG (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 7:1\u201359","journal-title":"Kidney Int Suppl"},{"key":"838_CR11","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2215\/CJN.12871211","volume":"7","author":"RH Yenchek","year":"2012","unstructured":"Yenchek RH, Ix JH, Shlipak MG et al (2012) Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 7:1130\u20131136","journal-title":"Clin J Am Soc Nephrol"},{"key":"838_CR12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfr317","volume":"27","author":"S Iimori","year":"2012","unstructured":"Iimori S, Mori Y, Akita W et al (2012) Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients\u2013a single-center cohort study. Nephrol Dial Transplant 27:345\u2013351","journal-title":"Nephrol Dial Transplant"},{"key":"838_CR13","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1111\/j.1600-6143.2008.02423.x","volume":"8","author":"S Akaberi","year":"2008","unstructured":"Akaberi S, Simonsen O, Lindergard B, Nyberg G (2008) Can DXA predict fractures in renal transplant patients? Am J Transplant 8:2647\u20132651","journal-title":"Am J Transplant"},{"key":"838_CR14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/sdi.12423","volume":"28","author":"R Babayev","year":"2015","unstructured":"Babayev R, Nickolas TL (2015) Bone disorders in chronic kidney disease: an update in diagnosis and management. Semin Dial 28:645\u2013653","journal-title":"Semin Dial"},{"key":"838_CR15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00198-011-1568-3","volume":"23","author":"E Dall'Ara","year":"2012","unstructured":"Dall\u2019Ara E, Pahr D, Varga P, Kainberger F, Zysset P (2012) QCT-based finite element models predict human vertebral strength in vitro significantly better than simulated DEXA. Osteoporos Int 23:563\u2013572","journal-title":"Osteoporos Int"},{"key":"838_CR16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1159\/000510064","volume":"51","author":"E Benillouche","year":"2020","unstructured":"Benillouche E, Ostertag A, Marty C, Urena Torres P, Cohen-Solal M (2020) Cortical bone microarchitecture in dialysis patients. Am J Nephrol 51:833\u2013838","journal-title":"Am J Nephrol"},{"key":"838_CR17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/01.mnh.0000447014.36475.58","volume":"23","author":"R Babayev","year":"2014","unstructured":"Babayev R, Nickolas TL (2014) Can one evaluate bone disease in chronic kidney disease without a biopsy? Curr Opin Nephrol Hypertens 23:431\u2013437","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"838_CR18","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.semnephrol.2014.09.004","volume":"34","author":"PU Torres","year":"2014","unstructured":"Torres PU, Bover J, Mazzaferro S, de Vernejoul MC, Cohen-Solal M (2014) When, how, and why a bone biopsy should be performed in patients with chronic kidney disease. Semin Nephrol 34:612\u2013625","journal-title":"Semin Nephrol"},{"key":"838_CR19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11914-013-0142-7","volume":"11","author":"KK Nishiyama","year":"2013","unstructured":"Nishiyama KK, Shane E (2013) Clinical imaging of bone microarchitecture with HR-pQCT. Curr Osteoporos Rep 11:147\u2013155","journal-title":"Curr Osteoporos Rep"},{"key":"838_CR20","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/jmri.20807","volume":"25","author":"FW Wehrli","year":"2007","unstructured":"Wehrli FW (2007) Structural and functional assessment of trabecular and cortical bone by micro magnetic resonance imaging. J Magn Reson Imaging 25:390\u2013409","journal-title":"J Magn Reson Imaging"},{"key":"838_CR21","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1007\/s00198-012-1908-y","volume":"23","author":"S Jamal","year":"2012","unstructured":"Jamal S, Cheung AM, West S, Lok C (2012) Bone mineral density by DXA and HR pQCT can discriminate fracture status in men and women with stages 3 to 5 chronic kidney disease. Osteoporos Int 23:2805\u20132813","journal-title":"Osteoporos Int"},{"key":"838_CR22","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/jbmr.2176","volume":"29","author":"BC Silva","year":"2014","unstructured":"Silva BC, Leslie WD, Resch H et al (2014) Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res 29:518\u2013530","journal-title":"J Bone Miner Res"},{"key":"838_CR23","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00198-018-4468-y","volume":"29","author":"J Aleksova","year":"2018","unstructured":"Aleksova J, Kurniawan S, Elder GJ (2018) The trabecular bone score is associated with bone mineral density, markers of bone turnover and prevalent fracture in patients with end stage kidney disease. Osteoporos Int 29:1447\u20131455","journal-title":"Osteoporos Int"},{"key":"838_CR24","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.ajkd.2015.06.020","volume":"67","author":"NR Daya","year":"2016","unstructured":"Daya NR, Voskertchian A, Schneider AL et al (2016) Kidney function and fracture risk: the atherosclerosis risk in communities (ARIC) study. Am J Kidney Dis 67:218\u2013226","journal-title":"Am J Kidney Dis"},{"key":"838_CR25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","volume":"58","author":"AM Alem","year":"2000","unstructured":"Alem AM, Sherrard DJ, Gillen DL et al (2000) Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58:396\u2013399","journal-title":"Kidney Int"},{"key":"838_CR26","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.kint.2018.12.024","volume":"95","author":"P Evenepoel","year":"2019","unstructured":"Evenepoel P, Claes K, Meijers B et al (2019) Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. Kidney Int 95:1461\u20131470","journal-title":"Kidney Int"},{"key":"838_CR27","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","volume":"70","author":"M Jadoul","year":"2006","unstructured":"Jadoul M, Albert JM, Akiba T et al (2006) Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70:1358\u20131366","journal-title":"Kidney Int"},{"key":"838_CR28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrneph.2009.192","volume":"6","author":"HH Malluche","year":"2010","unstructured":"Malluche HH, Monier-Faugere MC, Herberth J (2010) Bone disease after renal transplantation. Nat Rev Nephrol 6:32\u201340","journal-title":"Nat Rev Nephrol"},{"key":"838_CR29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4330\/wjc.v6.i4.115","volume":"6","author":"T Stompor","year":"2014","unstructured":"Stompor T (2014) Coronary artery calcification in chronic kidney disease: an update. World J Cardiol 6:115\u2013129","journal-title":"World J Cardiol"},{"key":"838_CR30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00223-013-9790-y","volume":"94","author":"MB Schaffler","year":"2014","unstructured":"Schaffler MB, Cheung WY, Majeska R, Kennedy O (2014) Osteocytes: master orchestrators of bone. Calcif Tissue Int 94:5\u201324","journal-title":"Calcif Tissue Int"},{"key":"838_CR31","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","volume":"67","author":"SM Sprague","year":"2016","unstructured":"Sprague SM, Bellorin-Font E, Jorgetti V et al (2016) Diagnostic accuracy of bone turnover markers and bone histology in patients With CKD treated by dialysis. Am J Kidney Dis 67:559\u2013566","journal-title":"Am J Kidney Dis"},{"key":"838_CR32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.21037\/qims.2018.01.02","volume":"8","author":"GM Blake","year":"2018","unstructured":"Blake GM, Puri T, Siddique M, Frost ML, Moore AEB, Fogelman I (2018) Site specific measurements of bone formation using [(18)F] sodium fluoride PET\/CT. Quant Imaging Med Surg 8:47\u201359","journal-title":"Quant Imaging Med Surg"},{"issue":"Suppl 5","key":"838_CR33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/ndt\/15.suppl_5.8","volume":"15","author":"MA Ferreira","year":"2000","unstructured":"Ferreira MA (2000) Diagnosis of renal osteodystrophy: when and how to use biochemical markers and non-invasive methods; when bone biopsy is needed. Nephrol Dial Transplant 15(Suppl 5):8\u201314","journal-title":"Nephrol Dial Transplant"},{"key":"838_CR34","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.4081\/ejh.2011.e1","volume":"55","author":"MJ Galvao","year":"2011","unstructured":"Galvao MJ, Santos A, Ribeiro MD, Ferreira A, Nolasco F (2011) Optimization of the tartrate-resistant acid phosphatase detection by histochemical method. Eur J Histochem 55:e1","journal-title":"Eur J Histochem"},{"key":"838_CR35","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00467-020-04499-2","volume":"35","author":"EMD Soeiro","year":"2020","unstructured":"Soeiro EMD, Castro L, Menezes R et al (2020) Association of parathormone and alkaline phosphatase with bone turnover and mineralization in children with CKD on dialysis: effect of age, gender, and race. Pediatr Nephrol 35:1297\u20131305","journal-title":"Pediatr Nephrol"},{"key":"838_CR36","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.kint.2017.07.021","volume":"92","author":"A Pimentel","year":"2017","unstructured":"Pimentel A, Urena-Torres P, Zillikens MC, Bover J, Cohen-Solal M (2017) Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation. Kidney Int 92:1343\u20131355","journal-title":"Kidney Int"},{"key":"838_CR37","doi-asserted-by":"crossref","first-page":"962","DOI":"10.2215\/CJN.11031017","volume":"13","author":"P Khairallah","year":"2018","unstructured":"Khairallah P, Nickolas TL (2018) Management of osteoporosis in CKD. Clin J Am Soc Nephrol 13:962\u2013969","journal-title":"Clin J Am Soc Nephrol"},{"key":"838_CR38","first-page":"92","volume":"34","author":"ABFJ Pereira","year":"2020","unstructured":"Pereira ABFJ (2020) Kidney-induced osteoporosis: a new entity with a novel therapeutic approach. Port J Nephrol Hypert 34:92\u2013100","journal-title":"Port J Nephrol Hypert"},{"key":"838_CR39","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1046\/j.1523-1755.63.s85.13.x","volume":"85","author":"SM Araujo","year":"2003","unstructured":"Araujo SM, Ambrosoni P, Lobao RR et al (2003) The renal osteodystrophy pattern in Brazil and Uruguay: an overview. Kidney Int Suppl 85:S54\u2013S56","journal-title":"Kidney Int Suppl"},{"key":"838_CR40","first-page":"57","volume":"30","author":"B Piraino","year":"1988","unstructured":"Piraino B, Chen T, Cooperstein L, Segre G, Puschett J (1988) Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 30:57\u201362","journal-title":"Clin Nephrol"},{"key":"838_CR41","first-page":"437","volume":"13","author":"A Gerakis","year":"2000","unstructured":"Gerakis A, Hadjidakis D, Kokkinakis E, Apostolou T, Raptis S, Billis A (2000) Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol 13:437\u2013443","journal-title":"J Nephrol"},{"key":"838_CR42","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJM198502213120803","volume":"312","author":"DL Andress","year":"1985","unstructured":"Andress DL, Ott SM, Maloney NA, Sherrard DJ (1985) Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure. N Engl J Med 312:468\u2013473","journal-title":"N Engl J Med"},{"key":"838_CR43","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/ki.1987.75","volume":"31","author":"E Slatopolsky","year":"1987","unstructured":"Slatopolsky E (1987) The interaction of parathyroid hormone and aluminum in renal osteodystrophy. Kidney Int 31:842\u2013854","journal-title":"Kidney Int"},{"key":"838_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4235","author":"DE Robinson","year":"2020","unstructured":"Robinson DE, Ali MS, Pallares N et al (2020) Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a bi-national cohort analysis. J Bone Miner Res. https:\/\/doi.org\/10.1002\/jbmr.4235","journal-title":"J Bone Miner Res"},{"key":"838_CR45","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/jbmr.3961","volume":"35","author":"D Alarkawi","year":"2020","unstructured":"Alarkawi D, Ali MS, Bliuc D et al (2020) Oral bisphosphonate use and all-cause mortality in patients with moderate-severe (Grade 3B\u20135D) chronic kidney disease: a population-based cohort study. J Bone Miner Res 35:894\u2013900","journal-title":"J Bone Miner Res"},{"issue":"Suppl 3","key":"838_CR46","doi-asserted-by":"crossref","first-page":"S256","DOI":"10.1177\/089686080102103S45","volume":"21","author":"C Rodd","year":"2001","unstructured":"Rodd C (2001) Bisphosphonates in dialysis and transplantation patients: efficacy and safety issues. Perit Dial Int 21(Suppl 3):S256\u2013S260","journal-title":"Perit Dial Int"},{"key":"838_CR47","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1210\/clinem\/dgaa851","volume":"106","author":"A Broadwell","year":"2021","unstructured":"Broadwell A, Chines A, Ebeling PR et al (2021) Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab 106:397\u2013409","journal-title":"J Clin Endocrinol Metab"},{"key":"838_CR48","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1210\/jc.2014-1154","volume":"99","author":"CL Chen","year":"2014","unstructured":"Chen CL, Chen NC, Hsu CY et al (2014) An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab 99:2426\u20132432","journal-title":"J Clin Endocrinol Metab"},{"key":"838_CR49","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/jbmr.3676","volume":"34","author":"K Iseri","year":"2019","unstructured":"Iseri K, Watanabe M, Yoshikawa H et al (2019) Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized. Controlled Trial J Bone Miner Res 34:1014\u20131024","journal-title":"Controlled Trial J Bone Miner Res"},{"key":"838_CR50","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00198-019-05038-y","volume":"30","author":"H Hagino","year":"2019","unstructured":"Hagino H, Narita R, Yokoyama Y, Watanabe M, Tomomitsu M (2019) A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis. Osteoporos Int 30:2027\u20132037","journal-title":"Osteoporos Int"},{"key":"838_CR51","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000316708","volume":"33","author":"D Cejka","year":"2010","unstructured":"Cejka D, Kodras K, Bader T, Haas M (2010) Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): a pilot study. Kidney Blood Press Res 33:221\u2013226","journal-title":"Kidney Blood Press Res"},{"key":"838_CR52","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420","journal-title":"N Engl J Med"},{"key":"838_CR53","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jbmr.3735","volume":"34","author":"P Chavassieux","year":"2019","unstructured":"Chavassieux P, Chapurlat R, Portero-Muzy N et al (2019) Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment. J Bone Miner Res 34:1597\u20131608","journal-title":"J Bone Miner Res"},{"key":"838_CR54","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19\u201326","journal-title":"J Bone Miner Res"},{"key":"838_CR55","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"838_CR56","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM, Blicharski T, Goemaere S et al (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103:3183\u20133193","journal-title":"J Clin Endocrinol Metab"},{"key":"838_CR57","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1471-2369-15-190","volume":"15","author":"FL Goncalves","year":"2014","unstructured":"Goncalves FL, Elias RM, dos Reis LM et al (2014) Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol 15:190","journal-title":"BMC Nephrol"},{"key":"838_CR58","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/ki.2015.194","volume":"88","author":"AR Qureshi","year":"2015","unstructured":"Qureshi AR, Olauson H, Witasp A et al (2015) Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int 88:1356\u20131364","journal-title":"Kidney Int"},{"key":"838_CR59","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/ndt\/gfu301","volume":"30","author":"C Drechsler","year":"2015","unstructured":"Drechsler C, Evenepoel P, Vervloet MG et al (2015) High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 30:288\u2013293","journal-title":"Nephrol Dial Transplant"},{"key":"838_CR60","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1093\/ndt\/gft039","volume":"28","author":"L Viaene","year":"2013","unstructured":"Viaene L, Behets GJ, Claes K et al (2013) Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant 28:3024\u20133030","journal-title":"Nephrol Dial Transplant"},{"key":"838_CR61","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/ki.1981.149","volume":"20","author":"G Cournot-Witmer","year":"1981","unstructured":"Cournot-Witmer G, Zingraff J, Plachot JJ et al (1981) Aluminum localization in bone from hemodialyzed patients: relationship to matrix mineralization. Kidney Int 20:375\u2013378","journal-title":"Kidney Int"},{"key":"838_CR62","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev.me.37.020186.000455","volume":"37","author":"HG Nebeker","year":"1986","unstructured":"Nebeker HG, Coburn JW (1986) Aluminum and renal osteodystrophy. Annu Rev Med 37:79\u201395","journal-title":"Annu Rev Med"},{"issue":"Suppl 2","key":"838_CR63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/ndt\/17.suppl_2.21","volume":"17","author":"HH Malluche","year":"2002","unstructured":"Malluche HH (2002) Aluminium and bone disease in chronic renal failure. Nephrol Dial Transplant 17(Suppl 2):21\u201324","journal-title":"Nephrol Dial Transplant"},{"key":"838_CR64","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/ki.1986.246","volume":"30","author":"MC Faugere","year":"1986","unstructured":"Faugere MC, Malluche HH (1986) Stainable aluminum and not aluminum content reflects bone histology in dialyzed patients. Kidney Int 30:717\u2013722","journal-title":"Kidney Int"},{"key":"838_CR65","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0272-6386(85)80089-5","volume":"6","author":"WG Goodman","year":"1985","unstructured":"Goodman WG (1985) Bone disease and aluminum: pathogenic considerations. Am J Kidney Dis 6:330\u2013335","journal-title":"Am J Kidney Dis"},{"key":"838_CR66","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/ndt\/15.9.1328","volume":"15","author":"KA Smans","year":"2000","unstructured":"Smans KA, D\u2019Haese PC, Van Landeghem GF et al (2000) Transferrin-mediated uptake of aluminium by human parathyroid cells results in reduced parathyroid hormone secretion. Nephrol Dial Transplant 15:1328\u20131336","journal-title":"Nephrol Dial Transplant"},{"key":"838_CR67","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/ki.1989.136","volume":"35","author":"AJ Felsenfeld","year":"1989","unstructured":"Felsenfeld AJ, Rodriguez M, Coleman M, Ross D, Llach F (1989) Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease. Kidney Int 35:1371\u20131378","journal-title":"Kidney Int"},{"key":"838_CR68","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/01.mnh.0000133973.86816.e9","volume":"13","author":"GJ Behets","year":"2004","unstructured":"Behets GJ, Verberckmoes SC, D\u2019Haese PC, De Broe ME (2004) Lanthanum carbonate: a new phosphate binder. Curr Opin Nephrol Hypertens 13:403\u2013409","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"838_CR69","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1177\/0091270006289846","volume":"46","author":"M Pennick","year":"2006","unstructured":"Pennick M, Dennis K, Damment SJ (2006) Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J Clin Pharmacol 46:738\u2013746","journal-title":"J Clin Pharmacol"},{"key":"838_CR70","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1097\/01.ASN.0000133022.32912.95","volume":"15","author":"GJ Behets","year":"2004","unstructured":"Behets GJ, Dams G, Vercauteren SR et al (2004) Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol 15:2219\u20132228","journal-title":"J Am Soc Nephrol"},{"key":"838_CR71","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/j.1523-1755.2005.00281.x","volume":"67","author":"GJ Behets","year":"2005","unstructured":"Behets GJ, Verberckmoes SC, Oste L et al (2005) Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 67:1830\u20131836","journal-title":"Kidney Int"},{"key":"838_CR72","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1046\/j.1523-1755.63.s85.18.x","volume":"85","author":"PC D'Haese","year":"2003","unstructured":"D\u2019Haese PC, Spasovski GB, Sikole A et al (2003) A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 85:S73\u2013S78","journal-title":"Kidney Int Suppl"},{"key":"838_CR73","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/ndt\/gfq124","volume":"25","author":"N Carrillo-Lopez","year":"2010","unstructured":"Carrillo-Lopez N, Fernandez-Martin JL, Alvarez-Hernandez D et al (2010) Lanthanum activates calcium-sensing receptor and enhances sensitivity to calcium. Nephrol Dial Transplant 25:2930\u20132937","journal-title":"Nephrol Dial Transplant"},{"key":"838_CR74","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0272-6386(12)80497-5","volume":"17","author":"JT McCarthy","year":"1991","unstructured":"McCarthy JT, Hodgson SF, Fairbanks VF, Moyer TP (1991) Clinical and histologic features of iron-related bone disease in dialysis patients. Am J Kidney Dis 17:551\u2013561","journal-title":"Am J Kidney Dis"},{"key":"838_CR75","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/ndt\/5.9.781","volume":"5","author":"FL Van de Vyver","year":"1990","unstructured":"Van de Vyver FL, Visser WJ, D\u2019Haese PC, De Broe ME (1990) Iron overload and bone disease in chronic dialysis patients. Nephrol Dial Transplant 5:781\u2013787","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 3","key":"838_CR76","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/ndt\/13.suppl_3.46","volume":"13","author":"F Velasquez Forero","year":"1998","unstructured":"Velasquez Forero F, Altamirano E, Ramos PT (1998) High frequency of iron bone deposits in a Mexican population with renal osteodystrophy. Nephrol Dial Transplant 13(Suppl 3):46\u201350","journal-title":"Nephrol Dial Transplant"},{"key":"838_CR77","first-page":"239","volume":"5","author":"GF Van Landeghem","year":"1997","unstructured":"Van Landeghem GF, D\u2019Haese PC, Lamberts LV, De Broe ME (1997) Competition of iron and aluminum for transferrin: the molecular basis for aluminum deposition in iron-overloaded dialysis patients? Exp Nephrol 5:239\u2013245","journal-title":"Exp Nephrol"},{"key":"838_CR78","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.3390\/nu7042324","volume":"7","author":"L Toxqui","year":"2015","unstructured":"Toxqui L, Vaquero MP (2015) Chronic iron deficiency as an emerging risk factor for osteoporosis: a hypothesis. Nutrients 7:2324\u20132344","journal-title":"Nutrients"},{"key":"838_CR79","doi-asserted-by":"crossref","first-page":"i39","DOI":"10.1093\/ndtplus\/sfr166","volume":"5","author":"J Cunningham","year":"2012","unstructured":"Cunningham J, Rodriguez M, Messa P (2012) Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients. Clin Kidney J 5:i39\u2013i51","journal-title":"Clin Kidney J"},{"key":"838_CR80","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1525-139X.2008.00530.x","volume":"22","author":"JF Navarro-Gonzalez","year":"2009","unstructured":"Navarro-Gonzalez JF, Mora-Fernandez C, Garcia-Perez J (2009) Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. Semin Dial 22:37\u201344","journal-title":"Semin Dial"},{"key":"838_CR81","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1093\/clinchem\/45.9.1548","volume":"45","author":"PC D'Haese","year":"1999","unstructured":"D\u2019Haese PC, Couttenye MM, Lamberts LV et al (1999) Aluminum, iron, lead, cadmium, copper, zinc, chromium, magnesium, strontium, and calcium content in bone of end-stage renal failure patients. Clin Chem 45:1548\u20131556","journal-title":"Clin Chem"},{"key":"838_CR82","doi-asserted-by":"crossref","first-page":"380247","DOI":"10.1155\/2015\/380247","volume":"2015","author":"JH Huang","year":"2015","unstructured":"Huang JH, Cheng FC, Wu HC (2015) Low magnesium exacerbates osteoporosis in chronic kidney disease patients with diabetes. Int J Endocrinol 2015:380247","journal-title":"Int J Endocrinol"},{"key":"838_CR83","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1046\/j.1523-1755.1999.00740.x","volume":"56","author":"I Schrooten","year":"1999","unstructured":"Schrooten I, Elseviers MM, Lamberts LV, De Broe ME, D\u2019Haese PC (1999) Increased serum strontium levels in dialysis patients: an epidemiological survey. Kidney Int 56:1886\u20131892","journal-title":"Kidney Int"},{"key":"838_CR84","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1046\/j.1523-1755.2000.00938.x","volume":"57","author":"PC D'Haese","year":"2000","unstructured":"D\u2019Haese PC, Schrooten I, Goodman WG et al (2000) Increased bone strontium levels in hemodialysis patients with osteomalacia. Kidney Int 57:1107\u20131114","journal-title":"Kidney Int"},{"key":"838_CR85","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1046\/j.1523-1755.1998.00035.x","volume":"54","author":"I Schrooten","year":"1998","unstructured":"Schrooten I, Cabrera W, Goodman WG et al (1998) Strontium causes osteomalacia in chronic renal failure rats. Kidney Int 54:448\u2013456","journal-title":"Kidney Int"},{"key":"838_CR86","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1046\/j.1523-1755.2003.00809.x","volume":"63","author":"I Schrooten","year":"2003","unstructured":"Schrooten I, Behets GJ, Cabrera WE et al (2003) Dose-dependent effects of strontium on bone of chronic renal failure rats. Kidney Int 63:927\u2013935","journal-title":"Kidney Int"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-021-00838-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-021-00838-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-021-00838-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T19:21:34Z","timestamp":1618600894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-021-00838-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["838"],"URL":"https:\/\/doi.org\/10.1007\/s00223-021-00838-z","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"assertion":[{"value":"17 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ana Carina Ferreira reports personal fees from Amgen and Viphor Pharma for giving lectures, outside the submitted work; Martine Cohen-Solal has no conflict of interest; Patrick C. D\u2019Haese reports research grants from Vifor Pharma, Inositec, Rockwell Medical, Sanifit, Fresenius Medical Care, Oxthera, Shire Pharmaceuticals, and Amgen, outside the submitted work; An\u00edbal Ferreira reports personal fees, grants, and participation in advisory boards from Abbvie, Astellas, Amgen, Baxter, Merck Sharp and Dhome, Mundipharma, Nephrocare-Fresenius Medical Care, Sanofi, and Vifor Pharma, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}